Clinical trials: Obinutuzumab, open to volunteers
Non-Hodgkin Lymphoma, B-cell
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
The goal of the study is to assess the safety and anti-lymphoma activity of MEN1703 (Dapolsertib hydrochloride) when given as a single-agent or combined with glofitamab to patients with relapsed/refractory (R/R) aggressive B-cell…
- Trial name
- JASPIS-01 (NCT06534437)
- Testing
- MEN1703, Glofitamab
- Where
- 35 sites in France, Poland and 2 more
- Volunteers
- 178 people
- Sponsor
- Ryvu Therapeutics SA
Mature B-cell Malignancies
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies
Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ICP-248 as monotherapy or in combination with anti-CD20 monoclonal antibody in Mature B-cell Malignancies
- Trial name
- NCT06351527
- Testing
- ICP-248, Obinutuzumab (G), Rituximab (R)
- Where
- 8 sites in United States, Puerto Rico and 1 more
- Volunteers
- 78 people
- Sponsor
- InnoCare Pharma Inc.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Obinutuzumab β
An Exploratory Study of Obinutuzumab β in the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy
This clinical trial aims to evaluate the safety and efficacy of obinutuzumab β in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The key research objectives are as follows:1.
- Trial name
- NCT07696377
- Testing
- Obinutuzumab β
- Volunteers
- 24 people
- Sponsor
- Zhongming Qiu
Multiple Myeloma, Relapsed, Multiple Myeloma (MM)
Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
This is a non-interventional observational study aiming to evaluate the quality of life, efficacy, and safety of advanced immuno-oncology agents versus conventional immuno-oncology therapies in patients with relapsed or…
- Trial name
- NCT07051850
- Testing
- Bispecific antibody, Antibody-Drug Conjugate, Monoclonal antibody
- Where
- South Korea
- Volunteers
- 174 people
- Sponsor
- Sung-Soo Park
Minimal Change Disease (MCD)
A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD)
OBELIX-NEPHROSIS (NS) The goal of this clinical trial is to learn if obinutuzumab works to treat minimal change disease in adults. It will also learn about the safety of drug obinutuzumab.
- Trial name
- OBELIX-NS (NCT07710157)
- Testing
- Obinutuzumab Injection, Predniso(lo)ne
- Where
- 6 sites in Austria, France and 1 more
- Volunteers
- 48 people
- Sponsor
- Medical University Innsbruck
Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL
This study is designed to evaluate the efficacy and safety of rimegepant in combination with glofitamab and CD19 CAR-T cell therapy in patients with high-risk relapsed/refractory large B-cell lymphoma.
- Trial name
- NCT07613788
- Testing
- Rimegepant, Glofitamab, Obinutuzumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Ruijin Hospital
Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN
Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial
:The aim of this study was to analyze the safety and efficacy of Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma with Prominent Nucleoli (SBLPN).
- Trial name
- ZGR in SBLPN (NCT07165769)
- Testing
- Induction Therapy, Maintenance Therapy
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Marginal Zone Lymphoma
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with obinutuzumab and lenalidomide in untreated marginal zone lymphoma.
- Trial name
- NCT06454968
- Testing
- Orelabrutinib, obinutuzumab, lenalidomide
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Peking Union Medical College Hospital
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Lymphoma
Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden
Glofitamab has shown efficacy and safety in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and has been approved for marketing in China.
- Trial name
- GLOHRT-01 (NCT06867536)
- Testing
- Glofitamab + Obinutuzumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Liling Zhang
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma…
- Trial name
- NCT06943872
- Testing
- Sonrotoclax, Obinutuzumab, Rituximab
- Where
- 195 sites in United States, Argentina and 19 more
- Volunteers
- 630 people
- Sponsor
- BeOne Medicines
Mantle Cell Lymphoma
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
This phase II trial studies the side effects of acalabrutinib, obinutuzumab, and glofitamab and how well they work together for treating patients with mantle cell lymphoma that has come back after a period of improvement…
- Trial name
- NCT06054776
- Testing
- Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- City of Hope Medical Center
Marginal Zone Lymphoma(MZL)
Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
This study focuses on treatment-naïve marginal zone lymphoma (MZL) patients and aims to investigate the efficacy and safety of orelabrutinib combined with or without CD20 monoclonal antibody.
- Trial name
- NCT07355699
- Testing
- Orelabrutinib
- Where
- 3 sites in China
- Volunteers
- 88 people
- Sponsor
- Beijing Tongren Hospital
Lupus Nephritis
PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN).
- Trial name
- NCT07611214
- Testing
- LUPKYNIS, belimumab, obinutuzumab or anifrolumab, mycophenolic acid analog (MPAA)
- Where
- 27 sites in United States
- Volunteers
- 150 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
This phase I/II trial tests the safety and effectiveness of glofitamab (with obinutuzumab pretreatment), venetoclax, and lenalidomide in treating patients with newly diagnosed, high risk mantle cell lymphoma.
- Conditions
- Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
- Trial name
- NCT05861050
- Testing
- Biopsy, Biospecimen Collection, Bone Marrow Biopsy
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- City of Hope Medical Center
Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
The researchers are doing this study to find out if the study treatment is an effective treatment that causes few or mild side effects in people with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), or…
- Trial name
- NCT06765317
- Testing
- Glofitamab, Polatuzumab, Rituximab
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
The goal of this phase II randomized open label study is to compare the rate of complete remission (CR) with undetectable minimal residual disease (uMRD) obtained with zanubrutinib in combination with obinutuzumab with two…
- Trial name
- NCT06544785
- Testing
- Zanubrutinib Oral Product, Obinutuzumab
- Where
- 19 sites in Spain
- Volunteers
- 106 people
- Sponsor
- PETHEMA Foundation
Follicular Lymphoma
Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma
This study is planned to prospectively evaluates the efficacy and safety of the zanubrutinib, obinutuzumab, and lenalidomide (ZGR) combination regimen in treatment-naïve follicular lymphoma (FL) patients in a Chinese population.
- Trial name
- ZGR in TN FL (NCT07299149)
- Testing
- Induction Therapy: Zanubrutinib, obinutuzumab, lenalidomide, Maintenance therapy: Zanubrutinib, lenalidomide
- Where
- 2 sites in China
- Volunteers
- 34 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Mantle Cell Lymphoma
Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy
This is a Phase 2, multicentre, single arm study that evaluates the efficacy and safety of glofitamab in MCL patients with inadequate response or relapse following CAR T-cell therapy.
- Trial name
- NCT07453095
- Testing
- Glofitamab
- Where
- 14 sites in Italy
- Volunteers
- 41 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a
Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody
The MIR study proved the effect of Rituximab in combination with a localized irradiation given in a standard dose. Together with the TROG 99.03 trial, this led to the recommendation of using this combined approach in early stage…
- Trial name
- FORTplus (NCT05045664)
- Testing
- Standard, Experimental
- Where
- 12 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Heidelberg University
Relapsed/refractory High Grade B Cell Lymphoma, High Grade B-cell Lymphoma
Immunotherapy in Lymphoma
The goal of this observational study is to compare the efficacy of advanced immunochemotherapy and classical immunochemotherapy in relapsed/refractory high grade B cell lymophoma patients.
- Conditions
- Relapsed/refractory High Grade B Cell Lymphoma, High Grade B-cell Lymphoma, Diffuse Large B Cell Lymphoma Relapsed, Primary Mediastinal Large B-Cell Lymphoma
- Trial name
- NCT06796517
- Testing
- CAR-T Therapy, Bispecific antibody, Antibody-Drug Conjugate
- Where
- 2 sites in South Korea
- Volunteers
- 72 people
- Sponsor
- Sung-Soo Park